incase you missed it

here it is again lol:

OBJ Limited (ACN 056 482 636)
Ground Floor, 284 Oxford Street, Leederville, Western Australia 6007
Phone: +61 8 9443 3011 Fax: +61 8 9443 3866 Email: [email protected]
Monday, 5 December 2005
100 FOLD INCREASE IN TRANSDERMAL
DELIVERY OF NALTREXONE
============================================
OBJ Limited (OBJ) announced today that results from independent University studies
had shown that the company’s transdermal drug delivery technology had successfully
delivered Naltrexone through-the-skin.
Naltrexone is an opioid antagonist used in the treatment of alcohol and heroin
addiction.
The study, conducted by the Western Australian Biomedical Research Institute
(WABRI) used donated human epidermis in an in-vitro transdermal diffusion study
which compared Dermaportation enhanced delivery against passive or unassisted
delivery. The results showed that Dermaportation could increase transdermal delivery
of Naltrexone by up to 100 times.
Naltrexone is a problematic drug in terms of administration. It is unsuited to oral
administration, due to poor bio-availability and adverse gastro-intestinal side-effects
which result in poor patient compliance. To overcome these difficulties Naltrexone is
usually administered via depot injections. The cost of this approach is high, labourintensive
and requires surgical conditions to administer. In addition, such system can
suffer from inconsistent delivery and release rates as well as local reactions.
Administering Naltrexone through the skin would avoid these problems, however
previous attempts have had limited success due to the size of the molecule, its
incompatibility with the skin and the need to achieve specific plasma concentrations.
The 100 fold increase in
delivery rates achieved by
the OBJ drug Patch
technology has the
potential to overcome
these difficulties.
As with a number of other
drugs and vaccines recently trialed, OBJ could be the first to market with a through-theskin
Naltrexone delivery solution.
Background to the Announcement
OBJ Limited is a drug delivery company, specializing in electronic “drug patch”
technologies that allow drugs, vaccines, therapeutic agents and cosmetic compounds
to be delivered more effectively and more efficiently through-the-skin.
The OBJ Dermaportation system has been shown to manage and control the
transdermal delivery of a broad range of drugs and therapeutic agents ranging from
small difficult molecules such as Caffeine, through to large macro-globular proteins
drugs such as vaccines.
OBJ’s technology has been independently proven in both in-vitro and in-vivo studies
and can manage a broader range of molecular sizes, structures and valencies than
other active or passive drug delivery systems.
OBJ has been successful in
managing the through-the-skin
delivery of drugs used in the
inflammation, pain, cancer and
cosmetic fields.
OBJ’s technology is low cost, and
can be incorporated into reusable
drug patches, (as illustrated)
disposable single use drug patches
and in a range of packaging
systems for OTC and retail use.
Sustainable Benefits
Low cost and controlled through-the-skin delivery of drugs, hormones, vitamins,
vaccines, anti-bodies and anti-aging molecules has long been the desire of the
pharmaceutical industry. It would provide economic, safety and efficacy benefits to the
pharmacology, medical, veterinary and cosmetic industries. Side effects could be
reduced by localized delivery and programmed delivery rates. Needle stick injuries and
needle disposable problems could be eliminated while the reduction in the level of skill
required for application could significantly reduce total cost of many health
programmes. These clear commercial benefits may only be achievable if the skin’s
natural barrier effect can be overcome.
OBJ is the first company to create a broad spectrum through-the-skin delivery system
that is kind to the skin, completely reversible, yet can handle drugs range from the
small difficult molecules up to the largest and most complex proteins and anti-bodies.
OBJ manages an extensive IP portfolio and prosecutes patent applications throughout
the world.
Independence of Results
OBJ contracts its drug and technology testing programs to independent and respected
organisations, such as Western Australian Biomedical Research Institute, Western
Australian Institute for Medical Research, Curtin University of Technology and Murdoch
University. The high level of independence and international accreditation means that
the results attributable to OBJ’s proprietary technology can be published and presented
at major medical and scientific conferences and forums.
For more information:
Jeffrey Edwards
Phone: +61 9 944 33011 Mobile: 041 791 2211 E-mail: [email protected]